NCT07403539

Brief Summary

Parkinson's disease, a common movement disorder that results from a breakdown in the brain, often leads to challenges with talking, but less is known about the relationship between difficulties with talking and difficulties with learning to understand speech. By linking these two abilities in individuals with Parkinson's disease using a precision medicine approach, this project seeks to build a basis for new therapies that help people with Parkinson's disease both understand better and speak more clearly.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
18mo left

Started Jan 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress20%
Jan 2026Dec 2027

First Submitted

Initial submission to the registry

January 27, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

January 27, 2026

Completed
15 days until next milestone

First Posted

Study publicly available on registry

February 11, 2026

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

February 11, 2026

Status Verified

February 1, 2026

Enrollment Period

1.9 years

First QC Date

January 27, 2026

Last Update Submit

February 4, 2026

Conditions

Keywords

speech perceptioncommunicationlearning

Outcome Measures

Primary Outcomes (5)

  • Mean dB SPL

    The mean speech intensity (in dB SPL) will be assessed using a recording of spoken sentences and a spoken paragraph.

    Day 1

  • Standard deviation dB SPL

    The standard deviation of participant's speech intensity (in dB SPL) will be assessed using a recording of spoken sentences and a spoken paragraph.

    Day 1

  • Speaking rate

    The speaking rate (in syllables/second) will be assessed using a recording of spoken sentences and a spoken paragraph.

    Day 1

  • Articulation rate

    The articulation rate (in syllables/second after removing pauses) will be assessed using a recording of spoken sentences and a spoken paragraph.

    Day 1

  • Unfilled pause time

    The unfilled pause time (in seconds of pause) will be assessed using a recording of spoken sentences and a spoken paragraph.

    Day 1

Study Arms (1)

Learning and Discrimination

EXPERIMENTAL

Behavioral interventions will be administered, including speech intensity learning, speech intensity discrimination, speech rate learning, and speech rate discrimination

Behavioral: Intensity learningBehavioral: Intensity discriminationBehavioral: Rate learningBehavioral: Rate discrimination

Interventions

Participants will be asked to pair sentences that vary in their sound intensity to one of three colored squares (red, yellow, or blue)

Learning and Discrimination

Participants will hear two sentences that are either the same or different in their sound intensity and will be asked to indicate whether the sentences were of the same or different intensities

Learning and Discrimination
Rate learningBEHAVIORAL

Participants will be asked to pair sentences that vary in their spoken rate to one of three colored squares (red, yellow, or blue)

Learning and Discrimination

Participants will hear two sentences that are either the same or different in their spoken rate and will be asked to indicate whether the sentences were of the same or different rates

Learning and Discrimination

Eligibility Criteria

Age45 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of Parkinson's disease
  • Native speaker of North American English
  • Use a drug that includes levodopa
  • Resident of the United States

You may not qualify if:

  • Any history of language, hearing or speech disorder outside of Parkinson's disease
  • Other gross neurological impairment such as Alzheimer's disease or stroke
  • Significant hearing loss and/or use of a hearing aid or cochlear implant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

State University of New York at Buffalo

Buffalo, New York, 14214, United States

RECRUITING

MeSH Terms

Conditions

Parkinson DiseaseCommunication

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative DiseasesBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

January 27, 2026

First Posted

February 11, 2026

Study Start

January 27, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

February 11, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

Deidentified speech perception and speech production data from individual participants

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Information will be available at the conclusion of data collection and will be available indefinitely
Access Criteria
Data and supporting material will be available on the Open Science Framework, a database that is open to the general public

Locations